AMICUS THERAPEUTICS, INC. — Director's Dealing 2015

Mar 24, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2015-03-20

Reporting Person: Campbell Bradley L (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-03-20	Common stock	M	12583	$11.5082	Acquired	212583	Direct
2015-03-20	Common stock	M	416	$11.5082	Acquired	212999	Direct
2015-03-20	Common stock	S	12999	$11.5082	Disposed	200000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-03-20	Stock Options (right to buy)	$4.16	M	12583	Disposed	2019-11-16	Common Stock (12583)	Direct
2015-03-20	Stocl Options (right to buy)	$2.81	M	416	Disposed	2020-06-15	Common stock (416)	Direct

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.

F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.93. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.93. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.